Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Sell

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Actinium Pharmaceuticals, Inc (ATNM)

Pharmaceutical Preparations

https://www.actiniumpharma.com

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

100 PARK AVE., 23RD FLOOR
NEW YORK, NY

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/19/2007

Market Cap

60,127,992

Shares Outstanding

27,410,000

Weighted SO

27,413,441

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

INKT --.--%

AFMD --.--%

IMGN --.--%

ADAP --.--%

SGMO --.--%

RIGL --.--%

FBIO --.--%

RVPH --.--%

CTIC --.--%

Beta

0.2000

Last Div

0.0000

Range

1.33-10.24

Chg

-0.0200

Avg Vol

739725

Mkt Cap

60127992

Exch

AMEX

Country

US

Phone

646 677 3870

DCF Diff

-0.7902

DCF

2.8002

Div Yield

0.0000

P/S

742.3209

EV Multiple

0.5241

P/FV

1.3254

Div Yield %

0.0000

P/E

-1.3631

PEG

0.0353

Payout

0.0000

Current Ratio

8.9502

Quick Ratio

8.9502

Cash Ratio

8.8443

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

4166.1754

CCC

-4166.1754

Gross Margin

-8.9259

Op Margin

-576.6543

Pretax Margin

-526.2099

Net Margin

-526.2099

Eff Tax Rate

-0.0225

ROA

-0.4743

ROE

-1.0169

ROCE

-0.5829

NI/EBT

1.0000

EBT/EBIT

0.9125

EBIT/Rev

-576.6543

Debt Ratio

0.0206

D/E

0.0422

LT Debt/Cap

0.0288

Total Debt/Cap

0.0405

Int Coverage

-85.3912

CF/Debt

-18.3672

Equity Multi

2.0500

Rec Turnover

0.0000

Pay Turnover

0.0876

Inv Turnover

0.0000

FA Turnover

0.0327

Asset Turnover

0.0009

OCF/Share

-1.1282

FCF/Share

-1.1295

Cash/Share

2.8581

OCF/Sales

-419.2716

FCF/OCF

1.0012

CF Coverage

-18.3672

ST Coverage

-61.6352

CapEx Coverage

-828.3171

Div&CapEx Cov

-828.3171

P/BV

1.3254

P/B

1.3254

P/S

742.3209

P/E

-1.3631

P/FCF

-1.7684

P/OCF

-1.7108

P/CF

-1.7108

PEG

0.0353

P/S

742.3209

EV Multiple

0.5241

P/FV

1.3254

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 25, 22:07 ATNM DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 27 Deadline in Securities Class Action – ATNM GlobeNewswire Inc. May 25, 22:07 ????? ?????? ?????? ??? ATNM: ????, ???? ????? ??? ???? ????, ????? ?? ?????? Actinium Pharmaceuticals, Inc ????? ?????? ?? ???? ?- 100 ??? ????, ?????? ????? ???? ????? ?????? ????? ?? 27 ???? ?????? ??????? ??????? ??? – ATNM GlobeNewswire Inc. May 21, 00:00 ATNM INVESTOR ALERT: Kirby McInerney LLP Reminds Actinium Pharmaceuticals, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit GlobeNewswire Inc. May 19, 23:40 ROSEN, A TOP RANKED LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM GlobeNewswire Inc. May 15, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and SoundHound and Encourages Investors to Contact the Firm GlobeNewswire Inc. Apr 29, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm GlobeNewswire Inc. Apr 22, 22:47 ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM GlobeNewswire Inc. Apr 22, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm GlobeNewswire Inc. Apr 18, 20:00 ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit GlobeNewswire Inc. Apr 16, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm GlobeNewswire Inc. Apr 12, 19:27 ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM MarketWatch Jan 06, 05:58 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks

Revenue Product Segmentation